Hybribio subsidiary amends medical device production license, expands scope

Guangdong Hybribio Biotech Co., Ltd. announced its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., received a revised medical device manufacturing license from the Guangdong Provincial Drug Administration. This amendment primarily concerns a change in the scope of production. The updated license will remain valid until January 8, 2029.

The revised production scope for Chaozhou Hybribio Biochemical Co., Ltd. now includes Class III 6840 in-vitro diagnostic reagents, Class II 18 obstetrics and gynecology, assisted reproduction, and contraception devices, and Class II 22 clinical laboratory instruments. The subsidiary's registered address is Guangdong Province, Chaozhou City, Economic Development Experimental Zone, North High-tech Zone D5-3-3-4.

Production activities will occur at two locations: Guangdong Province, Chaozhou City, Economic Development Experimental Zone, North High-tech Zone D5-3-3-4; and Chaozhou City, Xiangqiao District, Chuangbei Road No. 1, Hybribio Comprehensive Building, Fourth, Fifth, and Sixth Floors, Block B. This strategic update to the production license is expected to facilitate an expanded range of medical device manufacturing for the company.